Turner syndrome: diagnosis and management.
Turner syndrome occurs in one out of every 2,500 to 3,000 live female births. The syndrome is characterized by the partial or complete absence of one X chromosome (45,X karyotype). Patients with Turner syndrome are at risk of congenital heart defects (e.g., coarctation of aorta, bicuspid aortic valve) and may have progressive aortic root dilatation or dissection. These patients also are at risk of congenital lymphedema, renal malformation, sensorineural hearing loss, osteoporosis, obesity, diabetes, and atherogenic lipid profile. Patients usually have normal intelligence but may have problems with nonverbal, social, and psychomotor skills. Physical manifestations may be subtle but can include misshapen ears, a webbed neck, a broad chest with widely spaced nipples, and cubitus valgus. A Turner syndrome diagnosis should be considered in girls with short stature or primary amenorrhea. Patients are treated for short stature in early childhood with growth hormone therapy, and supplemental estrogen is initiated by adolescence for pubertal development and prevention of osteoporosis. Almost all women with Turner syndrome are infertile, although some conceive with assisted reproduction.
Morgan
Thomas
T
Washington University School of Medicine, St. Louis, Missouri 63110, USA. morgan_t@kids.wustl.edu
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D019465:Craniofacial Abnormalities / Q000209:etiology; D005260:Female; D006330:Heart Defects, Congenital / Q000209:etiology / Q000628:therapy; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D007621:Karyotyping; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D014424:Turner Syndrome / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*
D050071:Bone Density Conservation Agents; D019382:Human Growth Hormone